Omicron: Thailand, Indonesia plan to develop molnupiravir COVID-19 pills

THAILAND’S health minister said yesterday that the country planned to develop the anti-viral pill molnupiravir to combat COVID-19 infections amid rising infections driven by the Omicron variant.

The molnupiravir COVID-19 treatment pill for adult patients at risk of developing severe illness was jointly developed by US-based Merck & Co Inc and Ridgeback Biotherapeutics.

Thailand intends to join other countries in the region also planning to make versions of the drug, including Bangladesh and India.

“For molnupiravir, the Government Pharmaceutical Organization has plans to co-develop (this drug) with the Chulabhorn Research Institute,” Minister Anutin Charnvirakul told a news conference.

“A committee will research and produce the reactants, which will be additional support for future events,” he said.

Separately, Indonesia’s Health Minister Budi Gunadi Sadikin said yesterday the country also planned to develop molnupiravir in partnership with pharmaceutical company PT Amarox Pharma Global starting in April or May.

Indonesia approved molnupiravir for emergency use this week and 400,000 pills have arrived.

Thailand has ordered 50,000 courses of molnupiravir from Merck and was still in discussion with Pfizer for 50,000 courses of its drug Paxlovid. – Jan 15, 2022

Share on facebook
Share on twitter
Share on whatsapp
Share on email

Subscribe and get top news delivered to your Inbox everyday for FREE

Latest News